share_log
Benzinga ·  Mar 20 11:35
InflaRx's Cash, Cash Equivalents, And Marketable Securities Were €55.2M As Of December 31, 2024, Additional €28.7 Million (~$30M) In Gross Proceeds Subsequently Raised By An Underwritten Public Offering Extending Cash Runway Into 2027
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 301

Recommended

Write a comment